CD274 and hepatocellular carcinoma: A virus-like particle encapsulating a CpG-A TLR9 agonist (CMP-001) has recently been reported to cause tumor regression in syngeneic hepa1–6 mouse models of HCC, with a greater antitumor activity of CMP-001 monotherapy than that of sorafenib or PD-L1 blockade (196).